Changqing Xie, M.D., Ph.D.

Changqing Xie, M.D., Ph.D.
Physician-Scientist Early Investigator
Thoracic and GI Malignancies Branch

I am interested in exploring the potential mechanism of resistance to treatment with immune checkpoint inhibitor in gastrointestinal (GI) malignancy. My focus is to dissect the role of cancer stem cells in cholangiocarcinoma in terms of developing this therapy resistance.

Areas of Expertise

1) gastrointestinal (GI) malignancy, 2) cancer stem cells, 3) cholangiocarcinoma,
4) immune checkpoint inhibitor

Contact Info

Changqing Xie, M.D., Ph.D.
Center for Cancer Research
National Cancer Institute
Building 10, Room 3B43
Bethesda, Maryland 20892
Ph: 301-646-8337
changqing.xie@nih.gov

My overall goal is to explore the role of cancer stem cells in the development of treatment resistance to immunotherapy in cholangiocarcinoma with the following steps: 1) To investigate the path of cancer stem cells during cholangiocarcinoma; 2) To study the interaction between cancer stem cells and neighboring immune cells during cholangiocarcinoma pathogenesis; and 3) To identify the potential target agents to control cancer stem cells in cholangiocarcinoma.

NIH Scientific Focus Areas:
Cancer Biology, Clinical Research, Immunology, Molecular Biology and Biochemistry, Stem Cell Biology

Selected Recent Publications

  1. Immune Checkpoint Blockade in Combination with Stereotactic Body Radiotherapy in Patients with Metastatic Pancreatic Ductal Adenocarcinoma.
    Xie C, Duffy AG, Brar G, Fioravanti S, Mabry-Hrones D, Walker M, Bonilla CM, Wood BJ, Citrin DE, Gil Ramirez EM, Escorcia FE, Redd B, Hernandez JM, Davis JL, Gasmi B, Kleiner D, Steinberg SM, Jones JC, Greten TF.
    Clin Cancer Res. 26(10): 26(10):2318-26, 2020. [ Journal Article ]
  2. A Pilot Study of the PD-1 Targeting Agent AMP-224 Used With Low-Dose Cyclophosphamide and Stereotactic Body Radiation Therapy in Patients With Metastatic Colorectal Cancer.
    Floudas CS, Brar G, Mabry-Hrones D, Duffy AG, Wood B, Levy E, Krishnasamy V, Fioravanti S, Bonilla CM, Walker M, Morelli MP, Kleiner DE, Steinberg SM, Figg WD, Greten TF, Xie C.
    Clin Colorectal Cancer. 18(4): e349-e360, 2019. [ Journal Article ]
  3. Tremelimumab in combination with microwave ablation in patients with refractory biliary tract cancer.
    Xie C, Duffy AG, Mabry-Hrones D, Wood B, Levy E, Krishnasamy V, Khan J, Wei JS, Agdashian D, Tyagi M, Gangalapudi V, Fioravanti S, Walker M, Anderson V, Venzon D, Figg WD, Sandhu M, Kleiner DE, Morelli MP, Floudas CS, Brar G, Steinberg SM, Korangy F, Greten TF.
    Hepatology. 69(5): 2048-60, 2019. [ Journal Article ]
  4. The effect of anti-CTLA4 treatment on peripheral and intra-tumoral T cells in patients with hepatocellular carcinoma.
    Agdashian D, ElGindi M, Xie C (Co-first author), Sandhu M, Pratt D, Kleiner DE, Figg WD, Rytlewski JA, Sanders C, Yusko EC, Wood B, Venzon D, Brar G, Duffy AG, Greten TF, Korangy F.
    Cancer Immunol Immunother. 68(4): 599-608, 2019. [ Journal Article ]
  5. Case Report of an Adrenocortical Carcinoma Associated With Germline CHEK2 Mutation.
    Xie C, Tanakchi S, Raygada M, Davis JL, Del Rivero J.
    J Endocr Soc. 3(1): 284-90, 2018. [ Journal Article ]

I received my M.D. and Ph.D from the Xiangya School of Medicine of Central South University. I completed my postdoctoral training at Morehouse School Medicine and at the University of Michigan before being promoted as junior faculty at the University of Michigan. Before I started internal medicine residency training at East Carolina University, I worked as an Assistant Research Professor at the University of Virginia. I completed hematology oncology training through the NHLBI/NCI Hematology Oncology Fellowship program and joined the Thoracic and Gastrointestinal (GI) Malignancies Branch as an Assistant Clinical Investigator in 2019.

Name Position
Claude Fu Postdoctoral Fellow
Nicole A. McGrath Postbaccalaureate Fellow (CRTA)